Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947. The addition of this granted patent further strengthens Kuros' leading position in synthetic in-situ forming biomaterials.
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The Company's product candidates are based on two different matrix technology platforms. Kuros' most advanced candidate based on the synthetic technology to which this allowed patent application relates is KUR-023, Kuros' dural sealant. This product has successfully completed a European clinical study assessing its safety and efficacy and is being prepared for CE marking.
Kuros' other matrix technology is based on a fibrin matrix. The Company's most advanced fibrin matrix technology related product candidates, KUR-111 and KUR-113, have achieved positive results in large Phase II trials in bone repair indications.
Didier Cowling, Chief Executive Officer at Kuros, says: "This patent further builds on Kuros' proprietary position in synthetic hydrogel technology and strengthens the protection over its sealant product candidates."
The AI-Powered Lab Assistant with Scientific Awareness